Evaluation of HBs antibody titer of 10-18 years healthy students in Northeast of Iran by chemiluminescence assay

Authors

Abstract

Background and Objective: Hepatite B is one of the most important infection in the world. The best way to prevent hepatitis B infection is by getting the hepatitis B vaccine. The aim of this study was to evaluate level of HBs antibody titer of 10-18 years healthy students in Razavi Khorasan, North Khorasan and South Khorasan.
 
Materials and Methods: This study was a descriptive analytic research that was performed on 565 serum samples that were collected from 10-18 years healthy students with demographic information in Razavi Khorasan, North Khorasan and South Khorasan. HBs Ab titers were measured with immunochemiluminescence assay. Data were analyzed using Chi-Square and t test.
 
Results: Out of 565 students, 20.6% in Razavi Khorasan , 20.1% in North Khorasan and 22.4% in South Khorasan had antibody in protective range (>10 IU/L). In addition, 79.85% of students were non-immune. There was no significant difference in antibody among level of education, and urban and rural location. The relationship between sex and titer of anti HBs was not statistically significant. The highest percentage of students with protective antibody was observed in 10 years old students (33.3%) and there was the lowest level of protective antibody in 18 years old (15.4%).
 
Conclusion: HBs Ab titer of students should be regularly evaluated because HBsAb level decreases after certain periods as age advances. Awareness of students about injection of booster dose of hepatitis-B vaccine is required. 

Keywords

References

1. Michielsen P, Ho El. Viral hepatitis B and hepatocellular carcinoma. Acta gastro-enterologica Belgica 2011; 74(1): 4-8. 2. Wilkins T, Zimmerman D, Schade RR. Hepatitis B: Diagnosis and Treatment. American Academy of Family Physicians 2010; 81(8): 965-972. 3. World Health Organization (WHO). Hepatitis B. Geneva, Switzerland: World Health Organization. Updated July 2015. Available from: www.who.int/mediacentre/factsheets/fs204/en 4. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 2005; 34: 1329-1339. 5. Oakes K. Hepatitis B: prevalence and pathophysiology. Nurse Times 2014; 110(7): 12-16. 6. Wasley A, Kruszon-Moran D, Kuhnert W. The Prevalence of Hepatitis B Virus Infection in the United States in the Era of Vaccination. Journal of Infectious Diseases 2010; 202(2): 192-201. 7. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepatitis Monthly 2008; 8(4): 281-294. 8. Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. Iranian Journal of Clinical Infectious Diseases 2010; 5(1): 51-61. 9. Aspinall EJ, Hawkins G , Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational Medicine 2011; 61(8): 531–540. 10. Tazhibi M, Hajivandi A, Tafti AD, Fallahzadeh H. The efficacy of hepatitis B vaccine in Iranian population: A systematic review and meta-analysis. Journal of Education and Health Promotion 2014; 3: 53. 11. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational Medicine 2011;61:531–540. 12. Lu CY, Chang MH. Hepatitis B immunization: Is a booster necessary?. Hepatitis B Annual 2005; 2: 56-73. 13. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22-Year Follow-Up Study and Response to a Booster Dose. Journal of Infectious Diseases 2009; 200 (9): 1390-1396. 14. Hassan S, Ziba F. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine 2007; 25(17):3511-4. 15. Kelishadi R, Heshmat R, Motlagh ME, Majdzadeh R, Keramatian K, Qorbani M, et al. Methodology and early findings of the Third Survey of CASPIAN Study: A national school-based surveillance of students’ high risk behaviors. International Journal of Preventive Medicine. 2012;3:394-401. 16. Norouzirad R, Shakurnia AH, Assarehzadegan MA, Serajian A, Khabazkhoob M, et al. Serum Levels of Anti-Hepatitis B Surface Antibody Among Vaccinated Population Aged 1 to 18 Years in Ahvaz City Southwest of Iran. Hepatitis Monthly 2014; 14(1): e13625. 17. Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. Journal of Ayub Medical College Abbottabad 2006; 18(4): 4-9. 18. Tosun S, Deveci S, Kaplan Y, Kasirga E. Should a booster dose be administered in children after mass immunization for hepatitis B? Hepatitis Monthly 2011; 11(6):440–444. 19. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17(20-21):2661-6. 20. Aghakhani A, Banifazl M, Izadi N, McFarland W, Sofian M, Khadem-Sadegh A, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World Journal of Pediatrics 2011; 7(4): 358-60.
Daneshvar Medicine
Volume 25, Issue 3 - Serial Number 130
September and October 2017
Pages 67-72

Files

Share

How to cite

Statistics